Jeremy Loyau, PhDSenior Principal Scientist Display Technologies at Ichnos Sciences
Jeremy Loyau is Senior Principal Scientist at Ichnos responsible for the antibody discovery and optimization leading to the development of novel bi- or tri- specific immune engager therapeutics for cancer immunotherapy. He has led the implementation of Ichnos’ common light chain antibody discovery platform based on synthetic and immune phage display libraries and Next-Generation Sequencing of immune repertoires as a foundation of the BEAT 2.0 technology. He holds a PhD in biology from the University of Geneva and Novimmune where his research focused on antibody engineering using phage display and structural biology. He has published 2 first-author papers and is inventor on 4 patents application focusing on novel antibody therapeutics.